WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016095592) BCNU SUSTAINED-RELEASE IMPLANT FOR TREATING SOLID TUMOR AND PREPARATION METHOD THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/095592    International Application No.:    PCT/CN2015/091049
Publication Date: 23.06.2016 International Filing Date: 29.09.2015
IPC:
A61K 9/00 (2006.01), A61K 31/175 (2006.01), A61K 47/34 (2006.01)
Applicants: SHANDONG LANJIN PHARMACEUTICALS CO., LTD. [CN/CN]; 1750 Tian-chen Road, High-tech Industrial Development Zone Jinan, Shandong 250101 (CN)
Inventors: KONG, Qingzhong; (CN).
WEI, Mingxing; (CN).
SU, Hongqing; (CN).
WU, Songzhi; (CN).
YU, Jianjiang; (CN).
JIANG, Junmin; (CN).
LI, Zhaowen; (CN)
Agent: JINAN JINDI INTELLECTUAL PROPERTY AGENCY CO., LTD; No.27, Shanda South Road Jinan, Shandong 250199 (CN)
Priority Data:
201410778004.2 15.12.2014 CN
Title (EN) BCNU SUSTAINED-RELEASE IMPLANT FOR TREATING SOLID TUMOR AND PREPARATION METHOD THEREOF
(FR) IMPLANT À LIBÉRATION PROLONGÉE DE CARMUSTINE POUR LE TRAITEMENT DE TUMEURS SOLIDES ET SON PROCÉDÉ DE PRÉPARATION
(ZH) 一种治疗实体肿瘤的卡莫司汀缓释植入剂及其制备方法
Abstract: front page image
(EN)A BCNU sustained-release implant for treating solid tumor and preparation method thereof, the sustained-release implant comprising a sustained-release excipient and an effective anti-cancer ingredient BCNU; the sustained-release excipient is made from a copolymer of lactide and glycolide having a viscosity in a range of 0.3-0.6 dl/g; the percentage by weight of the BCNU is 7.5%-30%; the mass ratio of lactide to glycolide is (25-75) : (75-25). The implant is applied to treat solid tumors such as pancreatic cancer, lung cancer and the like, and liver and brain metastatic tumors.
(FR)L'invention concerne un implant à libération prolongée de carmustine pour le traitement de tumeurs solides qui comprend un excipient à libération prolongée désignant un copolymère lactide-glycolide dont la viscosité est de 0,3 et 06, dl/g et une carmustine anticancéreuse dont le rapport molaire est de 7,5 et 30 %, le rapport qualité du lactide et du glycolide étant de (25-75) : (75-25). L'implant est indiqué pour le traitement des tumeurs solides, des métastases du cerveau et du foie, comme par exemple mais non limitativement, le cancer du pancréas et le cancer du poumon.
(ZH)一种治疗实体肿瘤的卡莫司汀缓释植入剂,该缓释植入剂包括缓释辅料及抗癌有效成分卡莫司汀,缓释辅料为丙交酯-乙交酯共聚物,该共聚物粘度范围为0.3-0.6dl/g,卡莫司汀的重量百分比为7.5%-30%,丙交酯与乙交酯的质量比例为(25-75):(75-25)。该植入剂用于治疗胰腺癌、肺癌等实体肿瘤及肝脏、大脑转移瘤。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)